Ardea Biosciences Inc

Ardea Biosciences — Corporate Update (September 2009)

40 slides from Ardea Biosciences's corporate update, Sep 11, 2009

  1. Slide 1: Company Update September 11, 2009

    Company Update September 11, 2009

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results

  3. Slide 3: Five NCEs in Clinical Development for Four Indications

    Five NCEs in Clinical Development for Four Indications RDEA427 RDEA806 RDEA119 RDEA119/ RDEA436 Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV MEKI for cancer Inflammation 3 Gout RDEA594 RDEA684 MEKI + sorafenib for cancer RDEA119 Gout Partnered with Bayer

  4. Slide 4: Gout/Hyperuricemia

    Gout/Hyperuricemia Ardea) Biosciences

  5. Slide 5: Hyperuricemia/Gout - Unmet Medical Need

    Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL)Painful and debilitating diseaseAttacks of severe pain/InflammationDisfiguring nodules (tophi)Kidney damage (nephropathy)Increasing incidence and severity in U.S. (> 5,000,000 potential pati

  6. Slide 6: Refractory Disease Has Not Disappeared

    Refractory Disease Has Not Disappeared 6

  7. Slide 7: Rising Incidence Combined with Aging Population Will Lead to Sharp Increase in Patients

    Rising Incidence of Combined with Aging Population with Lead to Sharp Increase in Patients Arromdee et al. J Rheumatol. 2002;29:2403-2406. Incidence Rates x 100,000 People Age at Diagnosis of Gout (years) >2-fold increase in the rate of primary gout over the 2 time periods assessed 500 400 300 200 1

  8. Slide 8: Uric Acid Production and Elimination

    Hare, J. M. et al. Circulation 2003;107:1951-1953 Uric Acid Production and Elimination AllopurinolFebuxostat RDEA594ProbenecidBenzbromarone* 8 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. Pegloticase

  9. Slide 9: Competitive Landscape

    Competitive Landscape Allopurinol - Xanthine Oxidase Inhibitor40 year old generic xanthine oxidase inhibitor; 36-42% response rate and 8% SAEs in contemporary studies,1 and 0.4% incidence of hypersensitivity, which is 20-25% fatal2The combination of allopurinol and RDEA594 should be highly synergist

  10. Slide 10: Unmet Medical Need for New Urate-Lowering Therapy

    Unmet Medical Need for New Urate-Lowering Therapy 10 PLEASE RATE THE LEVEL OF UNMET MEDICAL NEED FOR NOVEL URATE- LOWERING THERAPY FOR PATIENTS WITH HYPERURICEMIA/GOUT (CHART)

  11. Slide 11: Unmet Medical Need for Novel Urate-Lowering Therapy Combined With Allopurinol

    Unmet Medical Need for Novel Urate-Lowering Therapy That Can Be Combined With Allopurinol 11 PLEASE RATE THE LEVEL OF UNMET MEDICAL NEED FOR AN ORAL URATE- LOWERING THERAPY WITH A NOVEL MECHANISM THAT CAN BE COMBINED WITH ALLOPURINOL (CHART)

  12. Slide 12: Selective URAT1 Transporter Inhibition: The Next Breakthrough in Hyperuricemia/Gout

    12 Selective URAT1 Transporter Inhibition: The Next Breakthrough in the Treatment of Hyperuricemia/Gout URAT1 inhibitorsNormalize renal clearance of uric acid (90% of gout patients are under-excretors of uric acid)Induce sustained reduction of serum urate levelHave been successfully combined with xa

  13. Slide 13: Allopurinol Results From Febuxostat Phase 3 Studies

    Allopurinol Results From Febuxostat Phase 3's 13 Febuxostat Phase 3 Study Results Febuxostat Phase 3 Study Results APEX 28-Week Study FACT 52-week Study CONFIRMS 28-Week Study Allopurinol 300/100mg QD (n=263) Allopurinol 300mg QD(n=242) Allopurinol 100/300mg QD(n=755) Proportion of patients at final

  14. Slide 14: Uric Acid-Lowering Was Noticed With RDEA806

    Uric Acid-Lowering Was Noticed With RDEA806 Up to 45% reductions in serum urate (sUA) were observed in healthy volunteers in the 10-day MAD studyUric acid reductions of were also observed in all HIV patients in the Phase 2a monotherapy study with RDEA806A 28-day proof-of-concept study with RDEA806 i

  15. Slide 15: RDEA594 Preclinical Background

    RDEA594 Preclinical Background RDEA594 is a selective inhibitor of the URAT1 renal transporter (EC50 = 5-10 ^M) without antiviral activityNo effect on OAT1 and OAT3 transporters (no interaction with antivirals or other drugs secreted by these transporters)Limited metabolism by CYP450 Inhibitors or i

  16. Slide 16: RDEA594 - Preclinical Safety Status

    RDEA594 - Preclinical Safety Status Chronic 6-month rat study has completed dosing13-week interim data including clinical chemistry and histopathology indicate no significant organ toxicity up to 300 mg/kg/day6-month data including gross observations consistent with 13-week results, histopathology p

  17. Slide 17: RDEA594, a Metabolite of RDEA806, Believed Responsible for Uric Acid Lowering

    <99%Reabsorption Secretion (~50%) Reabsorption (~10% fine tuning) Increased Excretion ~100% of uric acid is initially filtered through glomerular filtration RDEA594, a Metabolite of RDEA806, is Believed to be Responsible for Uric Acid Lowering URAT1 Enomoto; Urat1 identification in Nature May2002D L

  18. Slide 18: Steady-State Plasma Concentration Profiles of RDEA594 in MAD Study

    (CHART) Steady-State Plasma Concentration Profiles of RDEA594 in MAD Study 18 100 mg Solution (fed) 200 mg IR Capsules (fasted) 400 mg IR Capsules (fasted)

  19. Slide 19: Reduction of Serum Uric Acid by RDEA594 in MAD Study

    (CHART) Reduction of Serum Uric Acid by RDEA594 in MAD Study 19 *P<0.05, ** P<0.01, ***P<0.001 vs placebo ** *** *** ** ** ** ** *** *** *** *** ** ** * * * * *

  20. Slide 20: Phase 1 MAD Safety Summary

    Phase 1 MAD Safety Summary 20 Number of Subjects with Adverse Events - n (%) Number of Subjects with Adverse Events - n (%) Number of Subjects with Adverse Events - n (%) Number of Subjects with Adverse Events - n (%) Number of Subjects with Adverse Events - n (%) Number of Subjects with Adverse Eve

  21. Slide 21: RDEA594-102 MAD Safety Summary

    RDEA594-102 MAD Safety Summary No SAEs, deaths or discontinuations due to adverse events No clinically significant changes in physical exam findings or vital signsNo clinically significant changes in laboratory parameters except for changes in serum uric acid levels (desired pharmacological effect)N

  22. Slide 22: Promising Interim Results in RDEA594 Phase 2a Study in Gout Patients

    Arm 1:RDEA594 200 mg QD Promising Interim Results in RDEA594 Phase 2a Study in Gout Patients - Drug Works in Gout Patients Colchicine Treatment 7-21 days 1 weeks 2 weeks total with dose escalation of RDEA594 after Week 1 1 week Randomize if No gout flare during 2 weeks of colchicine Off drug Off dru

  23. Slide 23: RDEA594 Phase 2a Pilot Study in Gout Patients - Combination Arm Added

    Arm 1:RDEA594 200 mg QD RDEA594 Phase 2a Pilot Study in Gout Patients Combination Arm Added - Data at ACR Colchicine Treatment 7-21 days 1 weeks 2 weeks total with dose escalation of RDEA594 after Week 1 1 week Randomize if No gout flare during 2 weeks of colchicine Off drug Off drug Arm 2: Placebo

  24. Slide 24: Four Studies in Phase 2 Program Focus on Commercial Opportunities for RDEA594

    Four Studies in Phase 2 Program Focuses on Potential Commercial Opportunities for RDEA594 Monotherapyinadequate responders to allopurinolpatients who are intolerant to allopurinolfirst-line treatment (not primary target)Combination with allopurinol60% of allopurinol patients don't respond adequately

  25. Slide 25: RDEA594 Phase 2b Monotherapy Dose-Response, Safety and Efficacy Study

    RDEA594 Phase 2b Monotherapy Dose- Response, Safety and Efficacy Study 21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL)total of 160 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose will be titrated

  26. Slide 26: RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study

    RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study Dose Escalation Based on sUA Lowering with 200 mg RDEA594:18 patients including 12 patients randomized to RDEA594 and 6 patients randomized to placebo 26 RDEA594 100 mg and 300 mg or placebo plus allopurinol 300 mg RDEA594 200

  27. Slide 27: Gout/Hyperuricemia Program Summary

    27 There is a large unmet need for new treatments for this debilitating diseaseRDEA594, a selective URAT1 transport inhibitor, targets the physiologic cause of the vast majority of patients with hyperuricemia: uric acid under-excretionClinical proof-of-concept has been achieved, with statistically a

  28. Slide 28: HIV

    HIV Ardea) Biosciences

  29. Slide 29: RDEA806 Appears to Be an Ideal Candidate for the Majority of Naive HIV Patients

    RDEA806 Appears to Be an Ideal Candidate for the Majority of Naive HIV Patients Highly active against efavirenz-resistant strainsHigh genetic barrier to resistance Better safety profile than efavirenzReduced CNS toxicityImproved lipid profileEasy to formulate in combination pillOnce daily dosing (8

  30. Slide 30: Efavirenz is Not Suited for the Majority of Naive Patients

    Efavirenz is Not Suited for the Majority of Naive Patients *Estimates Out of 56,300 New Cases in 2006; CDC, New Estimates of HIV Infections The red slices represent new HIV patients where efavirenz is not the drug of choice, but where RDEA806 would be an ideal treatment. This represents >50% of the

  31. Slide 31: Robust Reductions in Viral Load with RDEA806 Monotherapy

    Days Robust Reductions in Viral Load with Monotherapy RDEA806* (CHART) Last Dose * Viral load reduction censored in 4 patients who reached 50 copies/ml LOQ of assay. Several patients started on triple therapy after Day 10 and prior to follow-up visit. 31

  32. Slide 32: RDEA427 Has Superior Resistance Profile to Other NNRTIs

    (CHART) RDEA427 Has Superior Resistance Profile to Other NNRTIs 32

  33. Slide 33: Cancer/Inflammation

    Cancer/Inflammation Ardea) Biosciences

  34. Slide 34: The Age of Targeted Cancer Treatments

    The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux ProliferationAngiogenesisDifferentiationApoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2)XL518 (Ph 1) RDEA119 (Ph 1/2) RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 34

  35. Slide 35: RDEA119 is Potent, Highly Specific MEK Inhibitor

    RDEA119 is Potent, Highly Specific MEK Inhibitor Inhibitor Inhibitor >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK1 & MEK2 0 20 40 60 80 100 Ron SRC RDEA

  36. Slide 36: Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines

    Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines (CHART) (CHART)

  37. Slide 37: RDEA119 Steady-State Plasma Concentrations in Advanced Cancer Patients

    RDEA119 Steady-State Plasma Concentrations in Advanced Cancer Patients 100 mg 60 mg 40 mg 30 mg 20 mg 10 mg 6 mg 4 mg 2 mg Shaded area represents Cmin free drug plasma levels observed in xenograft studies up to 25 mg/kg BID, which produced >100% tumor growth inhibition (TGI) QD Dose 37 Mean RDEA119

  38. Slide 38: Phase 1/2 Advanced Cancer Sorafenib Combination Study

    Study RDEA119-103 Primary Endpoint Safety and tolerability of RDEA119 in combination with sorafenib Secondary Endpoints PK, PD, efficacy Location University of Pennsylvania StudyPopulation Advanced cancer patients, all-comers until DLT reached, then expanded group of patients with specific tumors (r

  39. Slide 39: Financial Position Summary

    Financial Position Summary Statement of Operations(In thousands, except per share data) Six Months EndedJune 30, 2009 RevenueOperating expensesOther income (expense) $ 5,512 27,124 (454) NET LOSS $(22,066) NET LOSS PER SHARE $(1.23) 18.3 million common shares outstandingExpect 2009 year-end cash bal

  40. Slide 40: Near-Term Anticipated Milestones

    Near-Term Anticipated Milestones Near-Term Anticipated Milestones 40

Ardea Biosciences — Corporate Update (September 2009) on 6ix